Asia On The Move: Xian Janssen China President Thad Huston Leaves
This article was originally published in PharmAsia News
Executive Summary
The change of seasons coincides with a flurry of key personnel moves in the Asian pharmaceutical scene. Xian Janssen China President Thad Huston moves up, Simcere vice president Jie Liu D’Elia joins BMS. Personnel changes also took place in Takeda, Lupin, inVentive Health and the Japan Pharmaceutical Manufacturers Association.
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.